Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7192938 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(3 months from now) | |
US7718634 | APIL | Method of treatment using bisphosphonic acid |
May, 2023
(3 months from now) | |
US7718634
(Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(9 months from now) | |
US7192938
(Pediatric) | APIL | Method of treatment using bisphosphonic acid |
Nov, 2023
(9 months from now) |
Market Authorisation Date: 27 March, 1998
Treatment: Prevention and treatment of osteoporosis; Treatment of osteoporosis in postmenopausal women
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8246989 | APIL | Dosage forms of bisphosphonates |
Jan, 2026
(2 years from now) | |
US7645459 | APIL | Dosage forms of bisphosphonates |
Jan, 2028
(4 years from now) | |
US7645460 | APIL | Dosage forms of risedronate |
Jan, 2028
(4 years from now) |
Market Authorisation Date: 08 October, 2010
Treatment: Treatment of osteoporosis in postmenopausal women
Dosage: TABLET, DELAYED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic